In the article, Pharma’s Almanac collects inputs from many biotech and pharma companies about their thoughts on the most consequential event or result in pharma and biopharma in 2023.
Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, shares her thoughts highlighting that in 2023 the gene and gene-modified cell therapy sector experienced a significant increase in approvals which are expected to continue to grow. Natalia anticipates that the industry will require more skilled workers, and that their expertise and established experience will be crucial for success.
Natalia ends ups noting that VIVEbiotech has strengthened its capabilities and expertise by cultivating a highly skilled team characterized by a very low turnover rate.
You can read the full article here: https://www.pharmasalmanac.com/articles/what-do-you-think-was-the-single-most-consequential-event-or-result-in-pharma/biopharma-in-2023